CG Oncology, Inc. SEC Filings

CG Oncology, Inc. (CGON) director Christina Rossi has filed an initial insider ownership report indicating that she currently beneficially owns no securities of the company. Both the non-derivative and derivative security tables show no holdings, and the explanation section explicitly states that no securities are beneficially owned.

CG Oncology, Inc. appointed Christina Rossi to its Board of Directors, effective November 24, 2025, as a Class II director with a term running until the 2026 annual meeting of stockholders. Her compensation follows the company’s standard non-employee director program, including an annual cash fee of $45,000, paid quarterly, and an initial grant of 20,889 stock options that vest in equal monthly installments over three years, contingent on her continued service.

The company also reported that Simone Song resigned from the Board and all committees on November 22, 2025, effective immediately. The company stated that her resignation was not due to any disagreement with CG Oncology. Ms. Song had been a member of the Audit Committee and chair of the Compensation Committee.

CG Oncology, Inc. (CGON) filed a Form 3 reporting that its Interim Principal Financial and Accounting Officer, James M. DeTore, currently holds no beneficial ownership of the company’s securities. The filing identifies him as an officer of CG Oncology and confirms that no non-derivative or derivative securities are reported as beneficially owned. The Form 3 is filed by a single reporting person and serves as an initial ownership statement required under securities regulations.

CG Oncology, Inc. (CGON) director Leonard Post reported a small insider transaction involving company stock. On 11/17/2025, he exercised a director stock option to acquire 1,000 shares of common stock at an exercise price of $0.6 per share, then sold those 1,000 shares of common stock at a price of $41.43 per share. After these transactions, he reported owning 0 shares of common stock directly.

Following the option exercise, he continued to hold 117,077 derivative securities in the form of stock options, which are exercisable until 07/08/2028 and are fully vested. The filing notes that the sale was carried out under a Rule 10b5-1 trading plan that Leonard Post adopted on September 6, 2024, indicating the trades were pre-arranged under that plan.

CG Oncology (CGON) announced a finance leadership transition. Interim principal financial and accounting officer Robert Lapetina resigned effective November 30, 2025. The company appointed Jim DeTore as interim principal financial and accounting officer effective November 17, 2025, via a Consulting Agreement with Monomoy Advisors, LLC.

The agreement pays Monomoy Advisors $32,000 for November 2025 (prorated for a partial month) and $64,000 for each month thereafter, with a minimum three‑month term and an option to extend for an additional three months. Either party may terminate for a material breach not cured within 30 days of notice or for any reason with 60 days’ prior written notice.

DeTore previously served as CFO at Neurogastrx (June 2021–June 2025), Proteostasis Therapeutics (August 2016–February 2017), and Bluebird Bio (November 2014–February 2016), and consulted for biotech and pharma companies. He is eligible for the company’s standard indemnification agreement, and there are no disclosable related‑party transactions.

CG Oncology, Inc. filed its Q3 2025 report, showing total revenues of $1.666 million and a net loss of $43.808 million for the quarter. Operating costs were driven by research and development $27.884 million and general and administrative $23.334 million, offset by interest income $7.321 million.

Liquidity remains strong with approximately $680.3 million of cash, cash equivalents and marketable securities and working capital ~$665.3 million as of September 30, 2025. Under its at‑the‑market program, the company sold 1,515,151 shares at $33.00 for net proceeds $48.7 million in Q3, and subsequently sold 2,343,967 shares for net proceeds $98.4 million after quarter‑end.

CG Oncology consolidated Biovire following a July 2025 conversion event, recognizing $12.805 million of goodwill and $1.700 million in intangible assets; the total consideration was $26.844 million. The company reported positive clinical updates for cretostimogene, including a 24‑month complete response rate of 41.8% (46/110) in BOND‑003 Cohort C and initiated its BLA submission in Q4 2025. In litigation, a jury verdict favored the company regarding ANI’s claims, with no damages and no 5% royalty owed.

CG Oncology (CGON) furnished an update on its financial results under Item 2.02. The company announced it issued a press release covering results for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.

The company states the information in this report, including Exhibit 99.1, is being furnished and not filed pursuant to General Instruction B.2. The filing also lists the company’s common stock on The Nasdaq Global Select Market under the symbol CGON.

CG Oncology (CGON): Form 4 insider activity — A director reported transactions on 10/13/2025. The reporting person exercised 1,000 stock options at $0.60 (Code M) and sold 1,000 shares at $43.25 (Code S).

The sale was effected under a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person held 0 shares of common stock directly and 118,077 derivative securities (director stock options) directly.

Director James J. Mulay completed option-related transactions on 10/09/2025. He exercised 5,903 stock options at an exercise price of $3.72 per share, then sold the resulting 5,903 shares at $43.99 per share pursuant to a Rule 10b5-1 trading plan adopted on 06/06/2025. After these transactions the reporting person beneficially owns 0 shares of common stock and retains derivative exposure showing 1,962 derivative securities reported as beneficially owned following the transactions. The reported stock option vests in 36 monthly installments beginning on 07/14/2023 and has an expiration date of 06/13/2033. The Form 4 was signed on 10/10/2025 by an attorney-in-fact.